Welcome to the website of
The Blue Ridge Institute for Medical Research (BRIMR)
an independent non-profit organization founded in 2006
This site provides access to two unique BRIMR datasets:
- Authoritative annual rankings of NIH funding to individual researchers and academic institutions; and
- A comprehensive list of the chemical, pharmacological, and clinical characteristics of all protein-kinase inhibitor drugs approved by the FDA.
We are proud to make these data available as resources for the scientific community.
Status
The 2025 federal fiscal year ended on 30 September 2025. Fiscal 2026 is now underway.
NIH released its year-end summary of 2025 awards on 7 January 2026. BRIMR has drafted a modified version of that NIH dataset that more closely aligns with our ranking methodology. Our draft is now available for a four-week period of public review and input, after which it will serve as the basis for all of BRIMR’s 2025 rankings. We encourage all stakeholders to download our draft dataset, carefully review the listings for their own awards, and contact us with any suggested corrections before the review period ends at 5:00 PM Eastern time on Sunday 8 February 2026. Our final 2025 rankings will be released on this website shortly after the review period has ended, likely in early-to-mid-February.
Please be aware that this year, for the first time, BRIMR has instituted a new format for requesting corrections, as well as a processing fee of $20 per award for which one or more changes are requested. This processing fee is payable online at the time a request is made, regardless of whether any change is ultimately implemented; we accept most major credit cards and common digital wallets. No fee is charged for any modification that is made solely by BRIMR in keeping with its own policies. This modest fee will help support BRIMR’s staff, resources, and services to the academic community.
Complete data for prior years 2006-2024 are already available and can be accessed in the navigation menu at the top of this page.
Protein Kinase Inhibitors
There are 94 FDA-approved small molecule protein kinase inhibitors as of 30 October 2025. View them here.